|
Volumn 41, Issue 10, 2009, Pages 4246-4252
|
The Benefits of Interferon Treatment in Patients Without Sustained Viral Response After Living Donor Liver Transplantation for Hepatitis C
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ALANINE AMINOTRANSFERASE;
ASPARTATE AMINOTRANSFERASE;
BASILIXIMAB;
COLLAGEN TYPE 4;
CYCLOSPORIN A;
METHYLPREDNISOLONE;
MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;
PEGINTERFERON ALPHA2B;
PREDNISOLONE;
RECOMBINANT ALPHA2B INTERFERON;
RIBAVIRIN;
STEROID;
TACROLIMUS;
ADULT;
ALANINE AMINOTRANSFERASE BLOOD LEVEL;
ARTICLE;
ASPARTATE AMINOTRANSFERASE BLOOD LEVEL;
BLOOD SAMPLING;
CONTROLLED STUDY;
DISEASE COURSE;
DRUG DOSE ESCALATION;
DRUG DOSE TITRATION;
DRUG WITHDRAWAL;
FEMALE;
GRAFT SURVIVAL;
HEPATITIS C;
HEPATITIS C VIRUS;
HUMAN;
HUMAN TISSUE;
LIVER BIOPSY;
LIVER CELL CARCINOMA;
LIVER FIBROSIS;
LIVER GRAFT REJECTION;
LIVER HISTOLOGY;
LIVER TRANSPLANTATION;
LIVING DONOR;
MAJOR CLINICAL STUDY;
MALE;
PNEUMOCYSTIS PNEUMONIA;
PRIORITY JOURNAL;
PROTEIN BLOOD LEVEL;
SPLENECTOMY;
UNSPECIFIED SIDE EFFECT;
AGED;
ALANINE TRANSAMINASE;
ANTIVIRAL AGENTS;
ASPARTATE AMINOTRANSFERASES;
FEMALE;
GENOTYPE;
GRAFT SURVIVAL;
HEPATITIS C, CHRONIC;
HUMANS;
INTERFERON ALFA-2B;
LIVER TRANSPLANTATION;
LIVING DONORS;
MALE;
MIDDLE AGED;
POLYMERASE CHAIN REACTION;
RECURRENCE;
RETROSPECTIVE STUDIES;
RIBAVIRIN;
RNA, VIRAL;
SURVIVAL RATE;
|
EID: 71249097940
PISSN: 00411345
EISSN: None
Source Type: Journal
DOI: 10.1016/j.transproceed.2009.08.070 Document Type: Article |
Times cited : (14)
|
References (25)
|